AIMS/HYPOTHESIS: Fatty acids of marine origin, i.e. docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) act as hypolipidaemics, but they do not improve glycaemic control in obese and diabetic patients. Thiazolidinediones like rosiglitazone are specific activators of peroxisome proliferator-activated receptor gamma, which improve whole-body insulin sensitivity. We hypothesised that a combined treatment with a DHA and EPA concentrate (DHA/EPA) and rosiglitazone would correct, by complementary additive mechanisms, impairments of lipid and glucose homeostasis in obesity. METHODS: Male C57BL/6 mice were fed a corn oil-based high-fat diet. The effects of DHA/EPA (replacing 15% dietary lipids), rosiglitazone (10 mg/kg diet) or a combination of both on body weight, adiposity, metabolic markers and adiponectin in plasma, as well as on liver and muscle gene expression and metabolism were analysed. Euglycaemic-hyperinsulinaemic clamps were used to characterise the changes in insulin sensitivity. The effects of the treatments were also analysed in dietary obese mice with impaired glucose tolerance (IGT). RESULTS: DHA/EPA and rosiglitazone exerted additive effects in prevention of obesity, adipocyte hypertrophy, low-grade adipose tissue inflammation, dyslipidaemia and insulin resistance, while inducing adiponectin, suppressing hepatic lipogenesis and decreasing muscle ceramide concentration. The improvement in glucose tolerance reflected a synergistic stimulatory effect of the combined treatment on muscle glycogen synthesis and its sensitivity to insulin. The combination treatment also reversed dietary obesity, dyslipidaemia and IGT. CONCLUSIONS/ INTERPRETATION: DHA/EPA and rosiglitazone can be used as complementary therapies to counteract dyslipidaemia and insulin resistance. The combination treatment may reduce dose requirements and hence the incidence of adverse side effects of thiazolidinedione therapy.
AIMS/HYPOTHESIS: Fatty acids of marine origin, i.e. docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) act as hypolipidaemics, but they do not improve glycaemic control in obese and diabeticpatients. Thiazolidinediones like rosiglitazone are specific activators of peroxisome proliferator-activated receptor gamma, which improve whole-body insulin sensitivity. We hypothesised that a combined treatment with a DHA and EPA concentrate (DHA/EPA) and rosiglitazone would correct, by complementary additive mechanisms, impairments of lipid and glucose homeostasis in obesity. METHODS: Male C57BL/6 mice were fed a corn oil-based high-fat diet. The effects of DHA/EPA (replacing 15% dietary lipids), rosiglitazone (10 mg/kg diet) or a combination of both on body weight, adiposity, metabolic markers and adiponectin in plasma, as well as on liver and muscle gene expression and metabolism were analysed. Euglycaemic-hyperinsulinaemic clamps were used to characterise the changes in insulin sensitivity. The effects of the treatments were also analysed in dietary obesemice with impaired glucose tolerance (IGT). RESULTS:DHA/EPA and rosiglitazone exerted additive effects in prevention of obesity, adipocyte hypertrophy, low-grade adipose tissue inflammation, dyslipidaemia and insulin resistance, while inducing adiponectin, suppressing hepatic lipogenesis and decreasing muscle ceramide concentration. The improvement in glucose tolerance reflected a synergistic stimulatory effect of the combined treatment on muscle glycogen synthesis and its sensitivity to insulin. The combination treatment also reversed dietary obesity, dyslipidaemia and IGT. CONCLUSIONS/ INTERPRETATION:DHA/EPA and rosiglitazone can be used as complementary therapies to counteract dyslipidaemia and insulin resistance. The combination treatment may reduce dose requirements and hence the incidence of adverse side effects of thiazolidinedione therapy.
Authors: Jason K Kim; Jonathan J Fillmore; Oksana Gavrilova; Lily Chao; Takamasa Higashimori; Hyejeong Choi; Hyo-Jeong Kim; Chunli Yu; Yan Chen; Xianqin Qu; Martin Haluzik; Marc L Reitman; Gerald I Shulman Journal: Diabetes Date: 2003-06 Impact factor: 9.461
Authors: Saverio Cinti; Grant Mitchell; Giorgio Barbatelli; Incoronata Murano; Enzo Ceresi; Emanuela Faloia; Shupei Wang; Melanie Fortier; Andrew S Greenberg; Martin S Obin Journal: J Lipid Res Date: 2005-09-08 Impact factor: 5.922
Authors: Guenter Haemmerle; Robert Zimmermann; Marianne Hayn; Christian Theussl; Georg Waeg; Elke Wagner; Wolfgang Sattler; Thomas M Magin; Erwin F Wagner; Rudolf Zechner Journal: J Biol Chem Date: 2001-11-20 Impact factor: 5.157
Authors: H Kim; M Haluzik; O Gavrilova; S Yakar; J Portas; H Sun; U B Pajvani; P E Scherer; D LeRoith Journal: Diabetologia Date: 2004-12-15 Impact factor: 10.122
Authors: Martin Rossmeisl; Jan Kovar; Ivo Syrovy; Pavel Flachs; Dagmar Bobkova; Frantisek Kolar; Rudolf Poledne; Jan Kopecky Journal: Obes Res Date: 2005-05
Authors: Tomas Jelenik; Martin Rossmeisl; Ondrej Kuda; Zuzana Macek Jilkova; Dasa Medrikova; Vladimir Kus; Michal Hensler; Petra Janovska; Ivan Miksik; Marcin Baranowski; Jan Gorski; Sophie Hébrard; Thomas E Jensen; Pavel Flachs; Simon Hawley; Benoit Viollet; Jan Kopecky Journal: Diabetes Date: 2010-08-06 Impact factor: 9.461
Authors: Piotr Zabielski; Agnieszka Blachnio-Zabielska; Ian R Lanza; Srinivas Gopala; S Manjunatha; Daniel R Jakaitis; Xuan-Mai Persson; Jaime Gransee; Katherine A Klaus; Jill M Schimke; Michael D Jensen; K Sreekumaran Nair Journal: Am J Physiol Endocrinol Metab Date: 2013-12-24 Impact factor: 4.310